| Empagliflozin | Boehringer Ingelheim | ||
| 10, 25 mg; Tablet, Oral |
More Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
More Than 5
|
||
| None | None | ||
| Used to treat risk of cardiovascular death with patient with type 2 diabetes mellitus. | |||
|
Yes
| |||
| Jardiance | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | ****** *** | ****** *** | ******* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | ******* | ******* | **** ** **/******* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ******* ****** | ******* | *** ********* | *** ********* | ******* | *** ********* | ******* | ******* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ** *****'* | **** ** *** *, **** | **** *** | **** ** *** **, **** (**** ***) | ****** *** | ****** *** | **** ** *** **, **** | **** ** *** **, **** | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* ****** | *** \ *** | ***** **, **** | ******* | ********* ******** | ******* *** **** (******** ******) *** *** **** |
| ***** | *** \ *** | ***** **, **** | ******* | ********* ******** | *** ****** *** **** (******** ******) |
| ***** | *** \ ********* | *** *, **** | ******* | ********* ******** | ******* *** **** (******** ******) *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|